Espansione Group SpA

What Espansione Group SpA does

Espansione Group SpA is an Italian medtech company that designs, engineers, and manufactures certified light-based medical devices for ophthalmology and dermatology, headquartered in Funo (Bologna), Italy. Founded in 1981 by Rodolfo Pomar, the company's product ecosystem is built on two proprietary technology platforms: LM™ LLLT (Light Modulation™ Low-Level Light Therapy), a photobiomodulation technology originating from NASA research that uses multiple wavelengths (red 630nm, blue, yellow 590nm) to stimulate cellular ATP production; and OPE™ IPL (Optimal Power Energy™ Intense Pulsed Light), a software-controlled IPL system that delivers calibrated thermal pulses without protective gel. The flagship eye-light® device combines both technologies on a modular platform with up to nine expandable treatment protocols, addressing anterior segment conditions (dry eye disease, meibomian gland dysfunction, blepharitis, chalazion, Demodex, Sjögren's syndrome) and, since the 2025 CE (MDR) clearance, posterior segment dry age-related macular degeneration. Supporting products include meibomask® and my-mask® (LLLT masks), me-check® (the only CE Class II diagnostic device certified for use in optical centers), and young again® for dermatology and trichology.

Espansione sells primarily through direct sales to ophthalmologists, optometrists, eye clinics, and hospitals, supplemented by distributor networks (e.g., Axis Medical Canada), optical-center channels for me-check®, and a partner clinic network. Following the December 2024 acquisition by EssilorLuxottica (completed in 2025), distribution has been integrated into the parent's med-tech ecosystem alongside Heidelberg Engineering and RetinAI, extending reach into imaging and AI-augmented diagnostics. Products are sold as capital equipment with contact-based pricing; specific price points are not publicly disclosed. The company is present in over 50 countries and serves thousands of healthcare providers globally, with a current headcount in the 51–100 range. Revenue figures are not publicly disclosed, and no venture capital or private equity funding rounds are on record beyond a minor 2019 EISMEA grant.

Name

Espansione Group SpA

Legal name

Espansione Marketing S.p.A.

Website

https://espansionegroup.it

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

Espansione Group SpA is an Italian medtech company that designs and manufactures certified light-based medical devices—anchored by proprietary LM™ LLLT photobiomodulation and OPE™ IPL platforms—for ophthalmologists, eye clinics, and dermatology practitioners in over 50 countries. Since 2025 it has operated within the EssilorLuxottica med-tech ecosystem.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Optical Goods Retailers (456130)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

akta.pro secondary industries

Retina & Vitreous Specialists (HLAKAKAE), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI)

Keywords

• Ophthalmic medical devices
• Photobiomodulation therapy
• Ocular surface diagnostics
• Intense pulsed light systems
• Aesthetic dermatology devices

Headquarters

HQ city

Bologna

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Espansione Group generates revenue through the sale of certified medical devices including eye-light®, meibomask®, my-mask®, me-check®, and young again® systems. These are capital equipment purchases by healthcare providers and optical centers, representing the primary revenue stream.
2. Partnership and Distribution: Following acquisition by EssilorLuxottica in December 2024, Espansione Group operates within the EssilorLuxottica med-tech ecosystem, distributing through global distribution channels including the company's existing optical retail network and healthcare provider partnerships.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Espansione Group designs, engineers, and manufactures CE-marked medical devices that use proprietary light-based technologies (LM™ LLLT photobiomodulation and OPE™ IPL) to non-invasively diagnose and treat ocular surface conditions (dry eye, MGD, blepharitis, chalazion) and dry age-related macular degeneration, as well as dermatological and trichological indications. The product ecosystem spans screening (me-check®), in-clinic treatment (eye-light®, meibomask®), home-use therapy (my-mask®), and dermatology/aesthetic use (young again®), sold to healthcare professionals and clinics worldwide.

Product overview

Espansione Group SpA is an Italian medtech company (part of EssilorLuxottica since 2025) specializing in light-based therapeutic and diagnostic solutions. The core product ecosystem centers on the eye-light® platform—a modular dual-therapy medical device combining proprietary LM™ LLLT photobiomodulation (multiple wavelengths: red 630nm, blue, yellow 590nm) and OPE™ IPL technologies. The eye-light® platform serves both anterior segment (DED/MGD, blepharitis, chalazion, rosacea, Demodex, post-surgical) and posterior segment (dry AMD) ophthalmic applications, with up to nine expandable treatment protocols. Supporting the platform are meibomask® (professional LLLT mask for MGD/DED), my-mask® (portable home-use LLLT mask), me-check® (CE Class II certified diagnostic screening device for ocular surface evaluation), and young again® (dermatology/trichology device). The anterior segment portfolio addresses conditions including MGD/DED, blepharitis, chalazion, rosacea, Demodex, Sjögren's syndrome, and pre/post cataract and refractive surgery. The posterior segment offering targets dry age-related macular degeneration (dAMD) using photobiomodulation to address mitochondrial dysfunction. All solutions are designed, engineered, and manufactured in Italy.

Differentiator

Problem solved

Functional benefit

Products and services

• eye-light® Flagship dual-therapy medical device platform combining LM™ LLLT photobiomodulation (red, blue, yellow wavelengths) with OPE™ IPL technology to treat anterior segment conditions (DED/MGD, blepharitis, chalazion, Demodex, Sjögren's syndrome, pre/post cataract and refractive surgery) and posterior segment dry age-related macular degeneration. Features modular software-driven architecture with up to nine expandable treatment protocols and is CE (MDR) Marked for Dry AMD and extended anterior segment pathologies.
• meibomask® Professional-grade in-clinic photobiomodulation device utilizing LM™ LLLT technology to treat both upper and lower eyelids for maximum efficacy in managing dry eye disease, meibomian gland dysfunction, blepharitis, chalazion, and other ocular surface conditions.
• my-mask® Compact, portable LM™ LLLT red-light photobiomodulation mask for home-use treatment of dry eye disease induced by meibomian gland dysfunction, providing the clinic-grade therapeutic power in a lightweight form factor for patient convenience.
• me-check® CE Class II certified modular screening device for meibomian gland and ocular surface evaluation, including 2D/3D meibography, OSDI-6 questionnaire, interferometry, and blink quality testing. Incorporates the Meiboscale developed with Dr. Heiko Pult and OSDI-6 test with Prof. James Wolffsohn; the only certified device approved for use in optical centers, with diagnostic workflow completed in under 5 minutes.
• young again® All-in-one dermatology and trichology device using LM™ LLLT technology across red, blue, yellow, and infrared wavelengths for non-invasive treatment of skin and hair conditions including anti-aging, acne, scar treatment, and hair loss prevention and thickness improvement.

Quantifiable outcome

• Tear film quality nearly doubled with treatment, with over 70% of patients showing 10+ point improvement in Ocular Surface Disease Index (OSDI) after a single treatment
• +3 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, strategic and regional.

• EssilorLuxotticacoreStrategic or Co-development Partner · 17 December 2024EssilorLuxottica signed agreement to acquire Italy-based Espansione Group as part of its med-tech investment strategy. The acquisition expands EssilorLuxottica's portfolio of medical devices for diagnosing and treating dry-eye, ocular surface, and retinal diseases. The deal was completed in 2025, making Espansione Group part of the EssilorLuxottica med-tech ecosystem alongside Heidelberg Engineering, RetinAI, Pulse Audition, and Cellview.
• Visionix ItalystrategicChannel Partner/ Reseller/ Distributor · 30 April 2024Espansione Group announced exclusive partnership with Visionix Italy for distribution and collaboration in the Italian market. Visionix Italy is a provider of ophthalmic diagnostic equipment.
• Heidelberg EngineeringcoreTechnology or IntegrationBoth Heidelberg Engineering and Espansione Group are part of the EssilorLuxottica med-tech ecosystem. At RCOphth Annual Congress, companies exhibited together with combined ophthalmic solutions including SPECTRALIS imaging, ANTERION diagnostics, and eye-light photobiomodulation therapy.
• RetinAIcoreTechnology or IntegrationBoth RetinAI and Espansione Group are part of the EssilorLuxottica med-tech ecosystem. Companies mentioned together in LinkedIn post discussing collaboration on unlocking earlier insights, more precise diagnoses, and personalized treatment pathways through advances in med-tech including AI-powered analysis and innovative light-based therapies.
• Axis Medical CanadaregionalChannel Partner/ Reseller/ DistributorAxis Medical Canada is the Canadian distributor for Espansione Group's eye-light products. The distributor hosted educational webinars with Eye Recommend network featuring Dr. Paul Karpecki on Low-Level-Light Therapy.
• Eye RecommendregionalChannel Partner/ Reseller/ DistributorEye Recommend is a Canadian eye care network that hosted educational sessions on Espansione Group's LLLT technology in collaboration with Axis Medical Canada and Dr. Trevor Miranda.
• Dr. Heiko Pult and Prof. James WolffsohnstrategicStrategic or Co-development PartnerEspansione Group collaborated with Dr. Heiko Pult and Prof. James Wolffsohn to develop me-check®, incorporating the Meiboscale diagnostic scale and OSDI-6 questionnaire for standardized ocular surface disease assessment.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• LumiThera: Developer of the Valeda PBM system for dry age-related macular degeneration; directly competes with Espansione's eye-light® in the dry AMD photobiomodulation niche with overlapping clinical claims.
• Nova Eye Medical (formerly Ellex): Australia-based maker of ophthalmic laser and IPL platforms targeting glaucoma, vitreoretinal and dry eye/MGD indications; most direct competitor to eye-light® on the IPL side for anterior segment treatment.
• Quantel Medical: Lumibird subsidiary manufacturing ophthalmic ultrasound, laser and IPL systems for cataract, glaucoma and retinal care; competes on light-based therapeutic devices sold to ophthalmology practices.
• Lumenis: Originated IPL technology in ophthalmology (MGD/dry eye, OPT) and maintains a strong aesthetic/dermatology franchise; peer because of parallel IPL platform approach to DED and dermatology.
• IRIDEX Corporation: Developer of ophthalmic laser systems (retina and glaucoma segments, including transscleral and micropulse lasers); relevant peer in light-based ophthalmic therapy devices for specialist practices.

Broad incumbents

• Topcon Healthcare: Broad ophthalmic diagnostic and imaging equipment company with strong anterior/posterior segment offerings; partner of Espansione and broader incumbent across optical retail and clinical equipment.
• Carl Zeiss Meditec: Global leader in ophthalmic diagnostics, lasers and surgical microscopy; comparable as a broad-spectrum ophthalmic device manufacturer serving similar end customers.
• Nidek Co., Ltd. Japanese ophthalmic and optometric equipment manufacturer producing lasers, refractive surgery and diagnostic devices; comparable broad-line ophthalmic device vendor.
• Alcon: Global eye-care leader across surgical, vision care and ophthalmic pharmaceuticals; cited as Espansione partner and competing incumbent in anterior segment and ocular surface.

Emerging players

• Solta Medical (Bausch + Lomb): Developer of energy-based aesthetic devices (Clear+Brilliant, Thermage) using laser/IPL/RF; comparable to young again® in light-based aesthetic dermatology and trichology device category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/espansionegroup1981
• LinkedInlinkedin.com/company/espansione-group
• Instagraminstagram.com/espansionegroup

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Espansione Group SpA